Wellington Management Group LLP Acquires Shares of 34,751 Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

Wellington Management Group LLP bought a new position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 34,751 shares of the biotechnology company’s stock, valued at approximately $360,000.

Other large investors have also made changes to their positions in the company. Allspring Global Investments Holdings LLC purchased a new position in Enanta Pharmaceuticals during the 2nd quarter worth approximately $35,000. US Bancorp DE boosted its position in shares of Enanta Pharmaceuticals by 4,933.7% in the third quarter. US Bancorp DE now owns 4,329 shares of the biotechnology company’s stock worth $45,000 after buying an additional 4,243 shares during the period. Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Enanta Pharmaceuticals during the third quarter valued at $122,000. Quest Partners LLC raised its position in Enanta Pharmaceuticals by 511.2% during the second quarter. Quest Partners LLC now owns 11,588 shares of the biotechnology company’s stock valued at $150,000 after buying an additional 9,692 shares during the period. Finally, Valence8 US LP purchased a new stake in Enanta Pharmaceuticals in the 3rd quarter worth about $207,000. Institutional investors and hedge funds own 94.99% of the company’s stock.

Enanta Pharmaceuticals Stock Performance

NASDAQ:ENTA opened at $6.28 on Friday. The company has a market capitalization of $133.10 million, a P/E ratio of -1.15 and a beta of 0.49. The stock’s 50 day moving average price is $9.73 and its 200 day moving average price is $11.71. Enanta Pharmaceuticals, Inc. has a 52 week low of $5.70 and a 52 week high of $17.80.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings results on Monday, November 25th. The biotechnology company reported ($1.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.20). The business had revenue of $14.60 million for the quarter, compared to the consensus estimate of $17.99 million. Enanta Pharmaceuticals had a negative net margin of 171.57% and a negative return on equity of 73.02%. The firm’s revenue for the quarter was down 22.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($1.33) EPS. As a group, sell-side analysts forecast that Enanta Pharmaceuticals, Inc. will post -4.73 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. HC Wainwright reaffirmed a “buy” rating and set a $27.00 target price on shares of Enanta Pharmaceuticals in a research note on Thursday, October 10th. Robert W. Baird lowered their price objective on shares of Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 26th. Finally, JMP Securities reissued a “market outperform” rating and set a $21.00 target price (down previously from $22.00) on shares of Enanta Pharmaceuticals in a research note on Tuesday, November 26th. One research analyst has rated the stock with a sell rating, one has given a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $19.50.

Insider Buying and Selling at Enanta Pharmaceuticals

In other Enanta Pharmaceuticals news, CEO Jay R. Luly sold 5,142 shares of the stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $8.06, for a total transaction of $41,444.52. Following the transaction, the chief executive officer now owns 801,638 shares in the company, valued at $6,461,202.28. This trade represents a 0.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 13.64% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.